Bisphosphonate vs Denosumab: Which Is Better for Preventing Osteoporotic Fractures?

Direct Answer: Two Different Tools for the Same Job

Bisphosphonates and denosumab both reduce the risk of osteoporotic fractures, but they are not interchangeable. Bisphosphonates such as alendronate, risedronate, ibandronate, and zoledronic acid are taken orally (weekly or monthly) or given as an annual intravenous infusion, and they bind to bone where they suppress osteoclast activity for months to years. Denosumab (Prolia) is a monoclonal antibody injected under the skin every six months that blocks RANKL, a protein required for osteoclast formation. The 2009 FREEDOM trial published in The New England Journal of Medicine showed denosumab cut new vertebral fractures by 68%, hip fractures by 40%, and non-vertebral fractures by 20% over three years in postmenopausal women with osteoporosis. Oral bisphosphonates in landmark trials (FIT, HORIZON) typically reduce vertebral fracture risk by 40-70% and hip fracture risk by 20-40% over similar durations. Head-to-head DAPS and DECIDE trials found denosumab produced slightly larger BMD gains than alendronate, but no trial has shown a definitive mortality or fracture superiority of one class over the other.

Also worth reading: What are the official denosumab transition protocol guidelines for patients switching from or to bisphosphonate therapy? · What are the best COPD meal plan ideas for managing breathlessness and preventing weight loss? · What is the denosumab withdrawal fracture risk and how should patients manage it after stopping treatment?

How Each Drug Actually Works

Bisphosphonates are synthetic analogs of pyrophosphate that adhere to hydroxyapatite in bone. When osteoclasts resorb bone containing bisphosphonate, the drug disrupts their cytoskeleton and induces apoptosis. This produces a durable reduction in bone turnover that persists for years because the drug remains embedded in the skeleton; alendronate, for example, has a skeletal half-life estimated at more than 10 years. The 2010 NEJM paper on atypical femur fractures demonstrated that long-term bisphosphonate use (typically beyond 3-5 years) produces a measurable but small rise in AFF risk.

Denosumab is a fully human IgG2 monoclonal antibody that binds RANKL and prevents it from activating the RANK receptor on osteoclast precursors. Unlike bisphosphonates, denosumab does not deposit in bone. Its effect on bone resorption wanes within 6-9 months of the last injection, which is why missed or delayed doses cause rapid bone loss. A 2018 paper in The Journal of Clinical Endocrinology & Metabolism reported that discontinuation without follow-up bisphosphonate therapy led to 5-11% loss of lumbar spine BMD within 12 months and rebound vertebral fracture rates as high as 7.1 per 100 patient-years.

Practical Steps for Choosing Between Them

The 2020 AACE/ACE and 2024 updated Endocrine Society guidelines both endorse oral bisphosphonates as first-line therapy for most postmenopausal women with osteoporotic BMD (T-score ≤ -2.5) or fragility fractures. Denosumab is generally reserved for patients with impaired renal function (eGFR below 30-35 mL/min/1.73 m²), gastrointestinal intolerance to oral bisphosphonates, or those at very high fracture risk (T-score ≤ -3.0, recent hip or vertebral fracture, or multiple prior fractures). The AAFP Common Questions document emphasizes shared decision-making, baseline dual-energy X-ray absorptiometry (DXA), and a 10-year FRAX score before starting either agent. Calcium intake of 1,000-1,200 mg/day and vitamin D of 800-1,000 IU/day should accompany treatment regardless of drug choice. For those unable to sit upright for 30-60 minutes after dosing, oral bisphosphonates are contraindicated and IV zoledronate or denosumab is preferred.

Comparison Table: Side-by-Side at a Glance

The most frequent error with bisphosphonates is stopping after 1-2 years without reassessing; current guidance is to re-evaluate fracture risk after 3-5 years of oral or 3 years of IV therapy, then consider a "drug holiday" of 2-3 years for lower-risk patients. A 2021 Annals of Internal Medicine analysis noted that roughly 60% of patients discontinue oral bisphosphonates within 12 months, dramatically reducing real-world efficacy. With denosumab, the most dangerous mistake is stopping abruptly. The 2024 ASCO Post article on post-denosumab management in breast cancer patients treated with aromatase inhibitors stressed that any patient discontinuing denosumab must transition immediately to a bisphosphonate (typically zoledronic acid) to prevent rapid bone loss and rebound fractures. Patients also confuse the two drugs with each other; Prolia (60 mg every 6 months for osteoporosis) and Xgeva (120 mg every 4 weeks for bone metastases) are the same molecule at different doses and indications, but they are not interchangeable.

When to Act Quickly and When to Wait

A fragility fracture of the hip or vertebra is a red flag that mandates pharmacologic therapy within weeks, and denosumab is often favored in the very elderly because it avoids oral administration issues. A patient with a T-score of -1.5 plus a FRAX 10-year hip probability above 3% or major osteoporotic probability above 20% also meets treatment thresholds. Conversely, a premenopausal woman with a low-trauma wrist fracture and a T-score of -1.0 should first be evaluated for secondary causes (vitamin D deficiency, hyperparathyroidism, celiac disease) before committing to long-term therapy. The 2026 APCCC presentation on bone protection in patients on long-term androgen deprivation therapy noted that men starting ADT lose 2-6% of BMD per year and should receive a baseline DXA within weeks of starting therapy, with denosumab or zoledronic acid favored over oral agents because adherence tends to be higher.

Cost, Pricing, and Recent 2024-2026 Developments

Generic alendronate costs roughly $4-25 per month in the US, and annual zoledronic acid infusion averages $300-600 after infusion fees. Brand Prolia retails near $2,400 per dose in 2026, though Medicare Part B covers most of the cost for eligible beneficiaries. The FDA approved the first denosumab biosimilars (Spherix and others) in 2024-2025, and a 2025 Center for Biosimilars report showed a Chinese biosimilar matched reference denosumab for lumbar spine BMD in a 12-month study of postmenopausal women. List prices for biosimilars sit 30-60% below Prolia, which should narrow the cost gap by 2027. Until then, payers frequently require a trial of oral bisphosphonate before approving denosumab unless contraindicated. The 2026 atypical femur fracture NEJM analysis confirmed that AFF risk climbs after 3-5 years of bisphosphonate use but remains far lower than the fracture risk prevented, supporting continued treatment in high-risk patients.

When Each Drug Is the Wrong Choice

Oral bisphosphonates are inappropriate in patients with esophageal motility disorders, severe GERD, hypocalcemia, or eGFR below 30 mL/min/1.73 m² for oral forms; IV zoledronate can still be used with renal monitoring. Denosumab should not be given to patients with pre-existing severe hypocalcemia and should be used cautiously in those with advanced chronic kidney disease because of risks of adynamic bone disease. Pregnancy, breastfeeding, and pediatric osteoporosis outside of rare conditions are not approved indications for either class. Patients anticipating upcoming dental extractions or with active jaw osteonecrosis should not start either drug until the lesion resolves; ONJ rates remain low (0.01-0.1% for osteoporosis doses) but rise to 1-2% in cancer-dose regimens.

Bottom Line Guidance

For most adults newly diagnosed with osteoporosis, a generic oral bisphosphonate such as alendronate 70 mg weekly, or annual IV zoledronic acid 5 mg, offers the strongest evidence base, the lowest cost, and decades of safety data. Denosumab is the better choice when oral therapy is contraindicated or poorly tolerated, when renal function is severely reduced, or when fracture risk is so high that the rebound risk after stopping is outweighed by the immediate benefit. Any patient who starts denosumab must have a planned transition to a bisphosphonate if therapy is ever discontinued. Treatment duration, re-evaluation with DXA every 2-3 years, and lifestyle measures (weight-bearing exercise, fall prevention, adequate calcium and vitamin D) remain central to long-term fracture prevention regardless of drug choice.